Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336630 · ClinicalTrials.gov registry record · NA
Study of Forceps Cannulation During ERCP
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT05336630 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 152 participants.
The verdict
NCT05336630, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulation difficulty. The use of a forceps to assist in the cannulation is a demonstrated effective technique for cannulating papillae that are difficult to access. Thus, the objective of our study is to determine whether a forceps assisted cannulation leads to less difficult cannulation during ERCP. Because difficult cannulation is associated with increased risk of PEP, our study investigates whether the forceps assisted cannulation also reduces the incidence of PEP as a secondary outcome. Eligible patients who have consented will either be randomized to cannulation with forceps or cannulation with no forceps.
Interventions
- DEVICE Forceps
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2024-10-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336630
The ClinicalTrials.gov registry entry for NCT05336630 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Forceps is the first listed.
NCT05336630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05336630 about?
NCT05336630 is a clinical study titled "Study of Forceps Cannulation During ERCP". A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulation difficulty. The use of a forceps to assist in the cannulation is a demonstrated effective techni...
What is the current status of trial NCT05336630?
This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2022-05-12. Estimated completion is 2024-10-21.
What interventions are being tested in trial NCT05336630?
The interventions under investigation include: Forceps (DEVICE).
Who is sponsoring clinical trial NCT05336630?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.